Skip to main content
SpringerLink
Log in

Iclaprim reduces risk of acute kidney injury, saves costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Patel N, et al. Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Clinical Drug Investigation : 13 Aug 2018. Available from: URL: http://doi.org/10.1007/s40261-018-0686-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iclaprim reduces risk of acute kidney injury, saves costs. PharmacoEcon Outcomes News 810, 17 (2018). https://doi.org/10.1007/s40274-018-5208-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5208-4

Search

Navigation